Merck has been forced to delay marketing plans for its combination
cholesterol drug MK-0524B following problems in formulating its
top-selling statin Zocor (simvastatin) with a new promising
compound under development, MK-524A.
In the face of generic competition, Abbott has asked Irish
biotechnology firm Elan to use its NanoCrystal technology to
develop an "all in one" oral dose formulation combining two
cholesterol drugs, AstraZeneca's Crestor...
Researchers think they have found a gene, which when disrupted
interferes with the ability to absorb lipids through the intestine.
The discovery has added to new insights into mechanisms behind
lipid and cholesterol processing, and...
Merck has signed a research and drug development agreement with
FoxHollow Technologies, which represents the first
pharmaceutical-medical device partnership aimed at identifying
cardiovascular biomarkers for use as diagnostics and...
AstraZeneca has forged a deal with US biotechnology company Avanir
Pharmaceuticals - valued at up to $340 million - for the
development of a new type of treatment for high cholesterol that
could be more effective than current drugs...
An emerging trend has identified an emergence of combination drugs,
which could be a solution to patient non-compliance, a major factor
in the rise of drug resistant microorganisms in the industrialised
The battle to gain control of the lucrative cholesterol-lowering
drug market intensified after Merck and Schering-Plough joined
forces to win Food and Drug Administration (FDA) approval for their
new entrant, Vytorin.
The global generics industry is growing at such a rate that it can
now support billion dollar companies, with activities crossing into
active pharmaceutical ingredient (API) production and R&D. This
shift in the sector - from...